319 related articles for article (PubMed ID: 26320171)
41. Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes.
Horova V; Hradilova N; Jelinkova I; Koc M; Svadlenka J; Brazina J; Klima M; Slavik J; Hyrslova Vaculova A; Andera L
FEBS J; 2013 Jul; 280(14):3436-50. PubMed ID: 23678861
[TBL] [Abstract][Full Text] [Related]
42. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
43. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Zhao X; Sun W; Puszyk WM; Wallet S; Hochwald S; Robertson K; Liu C
Tumour Biol; 2017 May; 39(5):1010428317699120. PubMed ID: 28459212
[TBL] [Abstract][Full Text] [Related]
44. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
45. Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway.
Lin T; Chen Y; Ding Z; Luo G; Liu J; Shen J
PLoS One; 2013; 8(5):e63966. PubMed ID: 23696862
[TBL] [Abstract][Full Text] [Related]
46. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
47. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
[TBL] [Abstract][Full Text] [Related]
48. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
[TBL] [Abstract][Full Text] [Related]
49. Dexamethasone induces pancreatic β-cell apoptosis through upregulation of TRAIL death receptor.
Suksri K; Semprasert N; Junking M; Kutpruek S; Limjindaporn T; Yenchitsomanus PT; Kooptiwut S
J Mol Endocrinol; 2021 Aug; 67(3):95-106. PubMed ID: 34223821
[TBL] [Abstract][Full Text] [Related]
50. ADAM15 in Apoptosis Resistance of Synovial Fibroblasts: Converting Fas/CD95 Death Signals Into the Activation of Prosurvival Pathways by Calmodulin Recruitment.
Janczi T; Böhm BB; Fehrl Y; DeGiacomo P; Kinne RW; Burkhardt H
Arthritis Rheumatol; 2019 Jan; 71(1):63-72. PubMed ID: 30003689
[TBL] [Abstract][Full Text] [Related]
51. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
52. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
53. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling.
Park SK; Sanders BG; Kline K
Breast Cancer Res Treat; 2010 Nov; 124(2):361-75. PubMed ID: 20157774
[TBL] [Abstract][Full Text] [Related]
54. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
56. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
57. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models.
Kim H; Buchsbaum DJ; Zinn KR
Mol Imaging Biol; 2016 Jun; 18(3):325-33. PubMed ID: 26552657
[TBL] [Abstract][Full Text] [Related]
58. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
59. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Cancer Res; ; . PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
